Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Ann Thor to Female

This is a "connection" page, showing publications Ann Thor has written about Female.

 
Connection Strength
  
 
 
0.401
  
  1. Wahdan-Alaswad RS, Edgerton SM, Salem H, Kim HM, Tan AC, Finlay-Schultz J, Wellberg EA, Sartorius CA, Jacobsen BM, Haugen BR, Liu B, Thor AD. Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. Clin Cancer Res. 2021 01 15; 27(2):585-597.
    View in: PubMed
    Score: 0.029
  2. Wahdan-Alaswad R, Fan Z, Edgerton SM, Liu B, Deng XS, Arnadottir SS, Richer JK, Anderson SM, Thor AD. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle. 2013 Dec 15; 12(24):3759-69.
    View in: PubMed
    Score: 0.018
  3. Deng XS, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, Wahdan-Alaswad R, Thor AD. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle. 2012 Jan 15; 11(2):367-76.
    View in: PubMed
    Score: 0.016
  4. Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle. 2011 Sep 01; 10(17):2959-66.
    View in: PubMed
    Score: 0.016
  5. Yang X, Yang S, McKimmey C, Liu B, Edgerton SM, Bales W, Archer LT, Thor AD. Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation. Carcinogenesis. 2010 Apr; 31(4):695-702.
    View in: PubMed
    Score: 0.014
  6. Liu B, Ordonez-Ercan D, Fan Z, Huang X, Edgerton SM, Yang X, Thor AD. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling. Mol Cancer Res. 2009 Nov; 7(11):1882-92.
    View in: PubMed
    Score: 0.014
  7. Thor AD, Edgerton SM, Jones FE. Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. Am J Pathol. 2009 Nov; 175(5):1802-9.
    View in: PubMed
    Score: 0.014
  8. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009 Jul 01; 8(13):2031-40.
    View in: PubMed
    Score: 0.013
  9. DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol. 2008 May 10; 26(14):2364-72.
    View in: PubMed
    Score: 0.012
  10. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer. 2007 May 01; 120(9):1874-82.
    View in: PubMed
    Score: 0.011
  11. Yang XH, Edgerton S, Thor AD. Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to radiation therapy. Int J Oncol. 2005 Jun; 26(6):1675-80.
    View in: PubMed
    Score: 0.010
  12. DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D, Thor AD. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol. 2005 Feb 20; 23(6):1152-60.
    View in: PubMed
    Score: 0.010
  13. Kosanke S, Edgerton SM, Moore D, Yang X, Mason T, Alvarez K, Jones L, Kim A, Thor AD. Mammary tumor heterogeneity in wt-ErbB-2 transgenic mice. Comp Med. 2004 Jun; 54(3):280-7.
    View in: PubMed
    Score: 0.009
  14. Yang X, Edgerton SM, Kosanke SD, Mason TL, Alvarez KM, Liu N, Chatterton RT, Liu B, Wang Q, Kim A, Murthy S, Thor AD. Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. Cancer Res. 2003 May 15; 63(10):2425-33.
    View in: PubMed
    Score: 0.009
  15. Jeruss JS, Liu NX, Chung Y, Magrane G, Waldman F, Edgerton S, Yang X, Thor AD. Characterization and chromosomal instability of novel derived cell lines from a wt-erbB-2 transgenic mouse model. Carcinogenesis. 2003 Apr; 24(4):659-64.
    View in: PubMed
    Score: 0.009
  16. Wellberg EA, Corleto KA, Checkley LA, Jindal S, Johnson G, Higgins JA, Obeid S, Anderson SM, Thor AD, Schedin PJ, MacLean PS, Giles ED. Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer. Breast Cancer Res. 2022 06 20; 24(1):42.
    View in: PubMed
    Score: 0.008
  17. Thor AD, Eng C, Devries S, Paterakos M, Watkin WG, Edgerton S, Moore DH, Etzell J, Waldman FM. Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. Hum Pathol. 2002 Jun; 33(6):628-31.
    View in: PubMed
    Score: 0.008
  18. Liu S, Edgerton SM, Moore DH, Thor AD. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res. 2001 Jun; 7(6):1716-23.
    View in: PubMed
    Score: 0.008
  19. Thor AD, Liu S, Edgerton S, Moore D, Kasowitz KM, Benz CC, Stern DF, DiGiovanna MP. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol. 2000 Sep 15; 18(18):3230-9.
    View in: PubMed
    Score: 0.007
  20. Thor AD, Liu S, Moore DH, Shi Q, Edgerton SM. p(21WAF1/CIP1) expression in breast cancers: associations with p53 and outcome. Breast Cancer Res Treat. 2000 May; 61(1):33-43.
    View in: PubMed
    Score: 0.007
  21. Thor AD, Liu S, Moore DH, Edgerton SM. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol. 1999 Feb; 17(2):470-7.
    View in: PubMed
    Score: 0.006
  22. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998 Sep 16; 90(18):1346-60.
    View in: PubMed
    Score: 0.006
  23. Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018 07 26; 3(14).
    View in: PubMed
    Score: 0.006
  24. Giles ED, Jindal S, Wellberg EA, Schedin T, Anderson SM, Thor AD, Edwards DP, MacLean PS, Schedin P. Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. Breast Cancer Res. 2018 06 14; 20(1):50.
    View in: PubMed
    Score: 0.006
  25. Lee H, Saini N, Howard EW, Parris AB, Ma Z, Zhao Q, Zhao M, Liu B, Edgerton SM, Thor AD, Yang X. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells. Sci Rep. 2018 05 01; 8(1):6829.
    View in: PubMed
    Score: 0.006
  26. Wellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, Foright RM, Dooley G, Edgerton SM, Jindal S, Johnson GC, Richer JK, Kabos P, Thor AD, Schedin P, MacLean PS, Anderson SM. The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer. Horm Cancer. 2017 12; 8(5-6):269-285.
    View in: PubMed
    Score: 0.006
  27. Checkley LA, Rudolph MC, Wellberg EA, Giles ED, Wahdan-Alaswad RS, Houck JA, Edgerton SM, Thor AD, Schedin P, Anderson SM, MacLean PS. Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression In Vivo. Cancer Prev Res (Phila). 2017 Mar; 10(3):198-207.
    View in: PubMed
    Score: 0.006
  28. Gari HH, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Torkko KC, Edgerton SM, Lucia MS, Ray R, Thor AD, Porter CC, Lambert JR. Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers. Oncotarget. 2016 Mar 29; 7(13):15757-71.
    View in: PubMed
    Score: 0.005
  29. Schneider BP, O'Neill A, Shen F, Sledge GW, Thor AD, Kahanic SP, Zander PJ, Davidson NE. Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer. 2015 Dec 22; 113(12):1651-7.
    View in: PubMed
    Score: 0.005
  30. Lyu H, Huang J, Edgerton SM, Thor AD, He Z, Liu B. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. Int J Clin Exp Pathol. 2015; 8(6):6143-56.
    View in: PubMed
    Score: 0.005
  31. Wahdan-Alaswad RS, Cochrane DR, Spoelstra NS, Howe EN, Edgerton SM, Anderson SM, Thor AD, Richer JK. Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Horm Cancer. 2014 Dec; 5(6):374-89.
    View in: PubMed
    Score: 0.005
  32. Eng Tan P, Benz CC, Dollbaum C, Moore DH, Edgerton SM, Zava DT, Thor AD. Prognostic value of Cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay. Ann Oncol. 1994 Apr; 5(4):329-36.
    View in: PubMed
    Score: 0.005
  33. Jindal S, Gao D, Bell P, Albrektsen G, Edgerton SM, Ambrosone CB, Thor AD, Borges VF, Schedin P. Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling. Breast Cancer Res. 2014 Mar 28; 16(2):R31.
    View in: PubMed
    Score: 0.005
  34. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, G?mez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014 Jan 22; 16(1):R7.
    View in: PubMed
    Score: 0.005
  35. Zhu P, Davis M, Blackwelder AJ, Bachman N, Liu B, Edgerton S, Williams LL, Thor AD, Yang X. Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev Res (Phila). 2014 Feb; 7(2):199-210.
    View in: PubMed
    Score: 0.005
  36. Thor AD, Yandell DW. Prognostic significance of p53 overexpression in node-negative breast carcinoma: preliminary studies support cautious optimism. J Natl Cancer Inst. 1993 Feb 03; 85(3):176-7.
    View in: PubMed
    Score: 0.004
  37. Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK, Liu B. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Res. 2013; 15(5):R101.
    View in: PubMed
    Score: 0.004
  38. Giles ED, Wellberg EA, Astling DP, Anderson SM, Thor AD, Jindal S, Tan AC, Schedin PS, Maclean PS. Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. Cancer Res. 2012 Dec 15; 72(24):6490-501.
    View in: PubMed
    Score: 0.004
  39. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992 Jun 03; 84(11):845-55.
    View in: PubMed
    Score: 0.004
  40. Thor AD, Koerner FC, Edgerton SM, Wood WC, Stracher MA, Schwartz LH. pS2 expression in primary breast carcinomas: relationship to clinical and histological features and survival. Breast Cancer Res Treat. 1992; 21(2):111-9.
    View in: PubMed
    Score: 0.004
  41. Thor AD, Young RH, Clement PB. Pathology of the fallopian tube, broad ligament, peritoneum, and pelvic soft tissues. Hum Pathol. 1991 Sep; 22(9):856-67.
    View in: PubMed
    Score: 0.004
  42. Cajigas HE, Fariza E, Scully RE, Thor AD. Enhancement of tumor-associated glycoprotein-72 antigen expression in hormone-related ovarian serous borderline tumors. Cancer. 1991 Jul 15; 68(2):348-54.
    View in: PubMed
    Score: 0.004
  43. Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res. 2011 Aug 01; 17(15):5170-8.
    View in: PubMed
    Score: 0.004
  44. Schwartz LH, Koerner FC, Edgerton SM, Sawicka JM, Rio MC, Bellocq JP, Chambon P, Thor AD. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res. 1991 Jan 15; 51(2):624-8.
    View in: PubMed
    Score: 0.004
  45. Lloveras B, Edgerton S, Thor AD. Evaluation of in vitro bromodeoxyuridine labeling of breast carcinomas with the use of a commercial kit. Am J Clin Pathol. 1991 Jan; 95(1):41-7.
    View in: PubMed
    Score: 0.004
  46. Das PM, Thor AD, Edgerton SM, Barry SK, Chen DF, Jones FE. Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells. Oncogene. 2010 Sep 16; 29(37):5214-9.
    View in: PubMed
    Score: 0.004
  47. Thor AD, Edgerton SM. Monoclonal antibodies reactive with human breast or ovarian carcinoma: in vivo applications. Semin Nucl Med. 1989 Oct; 19(4):295-308.
    View in: PubMed
    Score: 0.003
  48. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007 Oct 11; 357(15):1496-506.
    View in: PubMed
    Score: 0.003
  49. Tophkhane C, Yang S, Bales W, Archer L, Osunkoya A, Thor AD, Yang X. Bcl-2 overexpression sensitizes MCF-7 cells to genistein by multiple mechanisms. Int J Oncol. 2007 Oct; 31(4):867-74.
    View in: PubMed
    Score: 0.003
  50. Kamath RV, Thor AD, Wang C, Edgerton SM, Slusarczyk A, Leary DJ, Wang J, Wiley EL, Jovanovic B, Wu Q, Nayar R, Kovarik P, Shi F, Huang S. Perinucleolar compartment prevalence has an independent prognostic value for breast cancer. Cancer Res. 2005 Jan 01; 65(1):246-53.
    View in: PubMed
    Score: 0.002
  51. Tedesco KL, Thor AD, Johnson DH, Shyr Y, Blum KA, Goldstein LJ, Gradishar WJ, Nicholson BP, Merkel DE, Murrey D, Edgerton S, Sledge GW. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol. 2004 Mar 15; 22(6):1071-7.
    View in: PubMed
    Score: 0.002
  52. Kashani-Sabet M, Liu Y, Fong S, Desprez PY, Liu S, Tu G, Nosrati M, Handumrongkul C, Liggitt D, Thor AD, Debs RJ. Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice. Proc Natl Acad Sci U S A. 2002 Mar 19; 99(6):3878-83.
    View in: PubMed
    Score: 0.002
  53. Scott GK, Chang CH, Erny KM, Xu F, Fredericks WJ, Rauscher FJ, Thor AD, Benz CC. Ets regulation of the erbB2 promoter. Oncogene. 2000 Dec 18; 19(55):6490-502.
    View in: PubMed
    Score: 0.002
  54. Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D, Norton L. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol. 2000 Oct 15; 18(20):3471-9.
    View in: PubMed
    Score: 0.002
  55. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000 Jul; 124(7):966-78.
    View in: PubMed
    Score: 0.002
  56. Stark A, Hulka BS, Joens S, Novotny D, Thor AD, Wold LE, Schell MJ, Melton LJ, Liu ET, Conway K. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol. 2000 Jan; 18(2):267-74.
    View in: PubMed
    Score: 0.002
  57. Wang C, Thor AD, Moore DH, Zhao Y, Kerschmann R, Stern R, Watson PH, Turley EA. The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res. 1998 Mar; 4(3):567-76.
    View in: PubMed
    Score: 0.002
  58. Krajewski S, Thor AD, Edgerton SM, Moore DH, Krajewska M, Reed JC. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin Cancer Res. 1997 Feb; 3(2):199-208.
    View in: PubMed
    Score: 0.001
  59. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science. 1996 Dec 20; 274(5295):2057-9.
    View in: PubMed
    Score: 0.001
  60. Zukerberg LR, Yang WI, Gadd M, Thor AD, Koerner FC, Schmidt EV, Arnold A. Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod Pathol. 1995 Jun; 8(5):560-7.
    View in: PubMed
    Score: 0.001
  61. Kupryjanczyk J, Bell DA, Dimeo D, Beauchamp R, Thor AD, Yandell DW. p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol. 1995 Apr; 26(4):387-92.
    View in: PubMed
    Score: 0.001
  62. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994 May 05; 330(18):1260-6.
    View in: PubMed
    Score: 0.001
  63. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, Yandell DW. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A. 1993 Jun 01; 90(11):4961-5.
    View in: PubMed
    Score: 0.001
  64. Louis DN, von Deimling A, Chung RY, Rubio MP, Whaley JM, Eibl RH, Ohgaki H, Wiestler OD, Thor AD, Seizinger BR. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol. 1993 Jan; 52(1):31-8.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)